Companies in #Immunotherapy

Elicio Therapeutics is a clinical-stage biotechnology company developing potent immunotherapies using its proprietary Amphiphile vaccine platform, which delivers immunogens directly to the lymph nodes to amplify immune responses against cancer. Its lead program ELI-002 is a KRAS-targeted cancer vaccine being studied in mKRAS-positive pancreatic ductal adenocarcinoma and other solid tumors. In June 2026 the Phase 2 AMPLIFY-201 trial missed its primary endpoint, sending shares down sharply, though the company said it will still advance to a Phase 3 study based on a subpopulation signal.

Commercial-stage immunotherapy company developing next-generation therapies that drive multiple innate and adaptive immune mechanisms, including the IL-15 superagonist ANKTIVA and Ad5/Ad26-based vaccine platforms, against cancer and infectious disease.

Clinical-stage immunotherapy company developing SurVaxM, a survivin-targeting cancer vaccine, for glioblastoma and other cancers.

Phanes Therapeutics is a clinical-stage biotechnology company focused on innovative drug discovery and development in oncology. Recently expanded its clinical trial collaboration with Merck to evaluate spevatamig in combination with KEYTRUDA for biliary tract cancer.

Rockville, Maryland-based clinical-stage biotechnology company developing orally delivered, precision-directed synthetic biology medicines that harness dendritic cells to control immune responses in cancer and autoimmune disease.